Open AccessCognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
Author(s) -
Small G. W.,
Kaufer D.,
Mendiondo M. S.,
Quarg P.,
Spiegel R.
Publication year - 2005
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1368-5031.2005.00524.x
Subject(s) - rivastigmine , medicine , placebo , acetylcholinesterase , butyrylcholinesterase , dementia , disease , donepezil , physical therapy , aché , biochemistry , chemistry , alternative medicine , pathology , enzyme
Summary This analysis aimed to assess mini‐mental state examination (MMSE) scores in patients with Alzheimer's disease who received rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, for up to 5 years. Rivastigmine data came from two pooled open‐label extensions of four 6‐month, randomised, placebo‐controlled trials. Projections of decline, had the same patients not been treated, were made using a baseline‐dependent mathematical model. MMSE data were available for 1998 rivastigmine‐treated patients and 657, 298 and 83 were still on treatment at 3, 4 and 5 years, respectively. The mean (±SD) baseline MMSE score was 19.3 (±4.9). Projected mean scores in model‐based untreated patients declined below 10 points on the MMSE at about 3 years, while the mean MMSE score of patients who remained on rivastigmine stayed above 10 points for 5 years.